Patients for whom treatment w/ both amlodipine & atorvastatin is considered appropriate: Amlodipine component
1st-line treatment of HTN & myocardial ischemia whether due to fixed obstruction (stable angina) &/or vasospasm/vasoconstriction (Prinzmetal's or variant angina) of coronary vasculature. Monotherapy or in combination w/ other antianginal drugs in patients w/ angina that is refractory to nitrates &/or adequate doses of β-blockers. Atorvastatin component
Adjunct to diet for patients w/ elevated total cholesterol (total-C), LDL-C, Apo B, triglycerides (TG) & to increase HDL-C in patients w/ primary hypercholesterolemia (heterozygous familial & nonfamilial), combined (mixed) hyperlipidemia (Fredrickson types IIa & IIb), elevated serum TG levels (Fredrickson type IV) & for patients w/ dysbetalipoproteinemia (Fredrickson type III) who do not respond adequately to diet. Reduction of total-C & LDL-C in patients w/ HoFH when response to diet & other non-pharmacological measures are inadequate. Prevention of CV disease in adult patients w/o clinically evident CHD but w/ multiple risk factors eg, age, smoking, HTN, low HDL-C, or family history of early CHD to reduce risk of MI, stroke, revascularisation procedures & angina. Patients w/ type 2 diabetes w/o clinically evident CHD but w/ multiple risk factors eg, retinopathy, albuminuria, smoking or HTN to reduce risk of MI & stroke. Patients w/ clinically evident CHD to reduce risk of non-fatal MI, fatal & non-fatal stroke, revascularisation procedures, hospitalisation for CHF & angina.